Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Lübbert, Michael  [Clear All Filters]
Journal Article
Baumann J, Spindler M, Throm Y, Lübbert M, Bender M. Absence of early platelet increment in healthy mice during decitabine treatment. Sci Rep. 2022;12(1):22266.
Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leuk Res. 2018;72:20-26.
Itzykson R, Santini V, Thépot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.
May AM, Stomper J, Joeckel TE, Bronsert P, Wijermans PW, Werner M, Lübbert M. Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine. Br J Haematol. 2020.
Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, et al. Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019:JCO1901406.
Schüller H, Klein F, Lübbert M, Prager EPeter. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol. 2020.
Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, et al. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res. 2019;85:106192.
Jung M, Herrlinger E-M, Hau M, Redhaber DMelanie, Greve G, Willmann D, Steimle S, Müller M, Lübbert M, Miething CCornelius, et al. Nitroreductase-mediated release of inhibitors of Lysine-Specific Demethylase 1 (LSD1) from prodrugs in transfected acute myeloid leukaemia cells. Chembiochem. 2020.